Holen Sie sich die Stockscreener-App
24.04
1.88%
-0.46
Handel nachbörslich:
24.04
Zenas Biopharma Inc Aktie (ZBIO) Neueste Nachrichten
A Look At Zenas BioPharma (ZBIO) Valuation After Recent Share Price Swings - simplywall.st
Tech Rally: Will Zenas BioPharma Inc benefit from geopolitical trendsJuly 2025 Outlook & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Zenas Biopharma Inc expected to post a loss of $1.03 a shareEarnings Preview - TradingView
Why Is ZBIO Stock Falling Pre-Market Today? - Stocktwits
ZBIO SEC FilingsZenas BioPharma Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Short Interest Up 18.8% in February - MarketBeat
The Bull Case For Zenas BioPharma (ZBIO) Could Change Following Obexelimab’s Commercial Pivot And Cash War Chest - simplywall.st
What is the target price for Zenas BioPharma Inc stockPortfolio Update Summary & Stock Timing and Entry Methods - baoquankhu1.vn
Zenas BioPharma, Inc. (NASDAQ:ZBIO) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Zenas BioPharma, Inc. (ZBIO): A Bull Case Theory - Insider Monkey
Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A 54.59% Potential Upside Awaits Investors - DirectorsTalk Interviews
Short Covering: Will Zenas BioPharma Inc outperform during market rallies - baoquankhu1.vn
A Look At Zenas BioPharma (ZBIO) Valuation As Obexelimab Shows Strong ACTRIMS 2026 Efficacy Data - simplywall.st
ZBIOZenas BioPharma Inc. Latest Stock News & Market Updates - Stock Titan
Zenas BioPharma (NASDAQ:ZBIO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Encouraging phase II trial data supported Zenas BioPharma (ZBIO) in Q4 - MSN
Encouraging Phase II Trial Data Supported Zenas BioPharma, Inc. (ZBIO) in Q4 - Finviz
Encouraging Phase II Trial Data Supported Zenas BioPharma (ZBIO) in Q4 - Insider Monkey
Why Zenas BioPharma (ZBIO) Is Up 24.6% After Obexelimab’s Phase 2 MS Trial SuccessAnd What's Next - Yahoo Finance
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap UpHere's Why - MarketBeat
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO) - PR Newswire
Street Watch: Is Zenas BioPharma Inc a good ESG investment2025 Analyst Calls & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Zenas BioPharma Highlights Obexelimab Phase 3 Win, Targets Q2 BLA Filing at Guggenheim Summit - MarketBeat
Fundamentals Check: Is Zenas BioPharma Inc stock a good pick for beginnersJuly 2025 Market Mood & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
What Wall Street predicts for Zenas BioPharma Inc. stock priceJuly 2025 Sector Moves & Stepwise Trade Signal Implementation - mfd.ru
Zenas BioPharma (NASDAQ:ZBIO) Director Buys $390,145.00 in Stock - MarketBeat
Hongbo Lu Buys 25,985 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Director Buys $109,657.60 in Stock - MarketBeat
Zenas BioPharma Adopts Amended Short-Term Incentive Plan - TipRanks
Zenas BioPharma, Inc. (ZBIO) Stock Analysis: A 56% Upside Potential In The Biotech Sector - DirectorsTalk Interviews
Insider Buying: Patricia Allen Acquires Shares of Zenas BioPharm - GuruFocus
Zenas BioPharma (NASDAQ:ZBIO) Trading 13.8% HigherWhat's Next? - MarketBeat
Will Zenas BioPharma Inc. outperform during market ralliesWeekly Trade Analysis & Low Risk Investment Opportunities - mfd.ru
Can Zenas BioPharma Inc. be the next market leaderTreasury Yields & Community Consensus Stock Picks - mfd.ru
ZBIO: Obexelimab shows strong efficacy, safety, and commercial promise in IgG4-RD and beyond - TradingView
Zenas BioPharma’s MS drug shows 95% reduction in brain lesions - Investing.com Nigeria
Zenas BioPharma approves 2026 inducement plan - MSN
HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
Zenas BioPharma’s MS drug shows 95% reduction in brain lesions By Investing.com - Investing.com Australia
Zenas BioPharma Meets Key Goal In Phase 2 MoonStone Trial Of Obexelimab In R/Multiple Sclerosis - RTTNews
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone ... - Bluefield Daily Telegraph
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026 - GlobeNewswire
Zenas Biopharma Announces Late-Breaking Platform Presentation Of Results From Phase 2 Moonstone Trial Of Obexelimab In Relapsing Multiple Sclerosis At Actrims Forum 2026 - TradingView
Insider Trends: Can Zenas BioPharma Inc be the next market leaderJuly 2025 Decliners & Entry Point Confirmation Alerts - baoquankhu1.vn
Zenas BioPharma (ZBIO) Price Target Increased by 10.51% to 44.44 - MSN
Does Zenas BioPharma (ZBIO) CEO’s Million‑Dollar Share Buy Reframe Management Credibility After Recent Setbacks? - Sahm
A Look At Zenas BioPharma (ZBIO) Valuation After Positive Phase 3 INDIGO Data And CEO Share Purchase - Sahm
Commit To Purchase Zenas Biopharma At $12.50, Earn 21.9% Annualized Using Options - Nasdaq
Zenas Bio rises after insider purchase by CEO (ZBIO:NASDAQ) - Seeking Alpha
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - marketscreener.com
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):